Fig. 3From: Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)Graphs of biochemical recurrence-free survival (BCRFS) and clinical progression-free survival (CPFS)Back to article page